From Skin Cells to Brain Transplantation: Two More Cohorts Complete Dosing With Personalized Cell Therapy for Parkinson’s Disease

For cell therapy for Parkinson’s disease to move beyond a small number of research centers, it must not only demonstrate that transplanted cells can survive in the brain, but also solve another practical challenge: how to manufacture and transport them reliably and use them on the day of surgery. Aspen Neuroscience announced that the Phase 1/2 ASPIRO trial has completed dosing in its third and fourth cohorts, bringing the total number of people who have received the personalized cell therapy sasineprocel, formerly known as ANPD001, to 15.

These two cohorts were the first to use what Aspen calls a “commercial-ready” formulation. The cells can be cryopreserved after manufacturing, then thawed upon arrival at the clinical center and injected directly, eliminating steps such as on-site preparation. This change does not mean the therapy has been approved for commercial use. Rather, it is intended to improve batch consistency, simplify distribution and surgical workflows, and prepare a more scalable manufacturing process for the company’s planned Phase 3 trial.

Sasineprocel begins with each patient’s own skin cells. Researchers reprogram them into induced pluripotent stem cells, then differentiate them into dopamine neuron precursor cells. Finally, using magnetic resonance imaging guidance, the cells are implanted into the brain’s putamen. These precursor cells are expected to mature in the body into dopamine-producing neurons in an attempt to replace neurological function progressively lost in Parkinson’s disease.

The autologous source offers one important potential advantage: the therapy is designed not to require long-term use of immunosuppressive drugs to prevent rejection. However, separately collecting samples, reprogramming cells, conducting quality testing, and manufacturing a product for each patient also make cost, delivery time, and product consistency barriers to commercialization. The frozen “thaw-and-inject” formulation improves the latter part of this supply chain but has not eliminated the inherent complexity of personalized production.

ASPIRO is an open-label, dose-escalation early-stage trial whose primary objective is to evaluate the safety and tolerability of the intracerebral implantation procedure and the cell product. The study will also track motor symptoms, medication-controlled “on” time, quality of life, and whether the transplanted cells survive, as assessed through magnetic resonance imaging and positron emission tomography. According to the trial registry, participants undergo assessments for five years after transplantation, followed by annual safety monitoring for another ten years.

This announcement did not provide new safety or efficacy results from the third and fourth cohorts, nor can it establish that the frozen formulation performs the same way in humans as the earlier formulation. ASPIRO has no randomized control group, and its sample size is also very small. Even if symptom improvements are observed later, factors including placebo effects, surgical effects, and adjustments to existing medications will still need to be ruled out.

Therefore, the completion of dosing in 15 people represents progress in manufacturing and clinical execution, not the emergence of a confirmed disease-modifying therapy for Parkinson’s disease. The next key question is whether the new formulation can maintain cell survival, safety, and functional performance, and whether it can translate into durable, clinically meaningful improvements in larger, controlled trials.